ShunzymeX Protease Technology for Scarless Affinity Purification

Technology
In market
University
Scouted & summarized by Halo AI

ShunzymeX is a precision microbial purification platform that streamlines downstream processing for complex biologics. By using an engineered, scarless protease, the technology enables the use of standard affinity resins to isolate proteins, followed by clean tag removal. This approach significantly reduces development timelines, improves yields, and simplifies the path to GMP-compliant manufacturing for pharmaceuticals and advanced therapies.

Overview

ShunzymeX is a precision purification technology designed to streamline the downstream processing of complex biological medicines. Developed through a strategic partnership between the University of Edinburgh and FUJIFILM Biotechnologies, this platform addresses significant bottlenecks in microbial protein production. By simplifying the purification workflow, the technology accelerates process development and facilitates a faster, more reliable transition from laboratory research to Good Manufacturing Practice (GMP) production. It provides a robust, scalable solution that improves yields and purity for a variety of microbial expression systems.

Technical specifications

The platform utilizes a proprietary, engineered protease that enables a scarless purification process. Key features include:

  • Enables the use of off-the-shelf affinity resins for protein isolation via an added affinity tag.
  • Employs a novel protease that precisely cleaves the tag post-purification.
  • Leaves the target therapeutic protein in its native form, with no unwanted amino acid residues remaining.
  • Designed to function optimally within the temperature and pH ranges required for large-scale industrial biologics manufacturing.
  • Scalable from process development (PD) directly into cGMP environments.
  • Compatible with diverse microbial expression systems, including E. coli and P. pastoris.
  • Designed for integration with automated downstream processing equipment such as the SymphonX platform.
Technology readiness level

The technology is currently at TRL 9. It has been successfully developed, validated, and launched as a commercial platform by FUJIFILM Biotechnologies, a leading global contract development and manufacturing organization (CDMO), with ongoing industry deployment for biologics manufacturing.

Generated Jul 8, 2026. Please verify key information.

About University of Edinburgh

The University of Edinburgh is a comprehensive, research‑intensive public university in Scotland’s capital. Industry engages through co‑located facilities and innovation hubs that bring companies into the university ecosystem, including the Bayes Centre for data and AI and the Usher Institute at the Edinburgh BioQuarter. Integration with NHS Lothian at BioQuarter places hospital care, clinics and university research on a single site to speed clinical studies and translation. Research is supported by competitive UK government funding via UKRI and Innovate UK, alongside major charitable funders such as Wellcome. A dedicated technology transfer company, Edinburgh Innovations, streamlines access to expertise, IP management, licensing and venture creation.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.